PBH logo

PRESTIGE CONSUMER HEALTHCARE

PBHNYSE
πŸ† #1916 by market capUS Equity
$46.73β–Ό $0.24 (βˆ’0.52%)
After hours Β· at close
πŸ””
Track PBH
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.5%
7dβ–Ό 2.1%
14dβ–² 0.1%
30dβ–Ό 11.0%
ytdβ–Ό 24.2%
1yβ–Ό 24.5%
🏦Market Cap
$2.21B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-4.3%
Declining
πŸ“ŠGross Margin
53.3%
Healthy
πŸ’΅FCF Margin
21.3%
Strong
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
76
Good

Trading Snapshot

Day Range
$46.26 – $47.60
52-Week Range
$42.62 – $71.07
Volume
$3.22B
Avg Volume
$3.72B
Shares Outstanding
47.4M
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$1.09B
Last Q Revenue
$266M
P/E Ratio
13.1
P/S Ratio
2.0x
EPS (TTM)
$3.62
Dividend Yield
0.00%
Dilution (1yr)
βˆ’1.0%

Why Investors Own PBH

  • βœ“High-growth profile β€” revenue up +31.9% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 63% gross margin and 24% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PBH logo

PRESTIGE CONSUMER HEALTHCARE

PBH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1Bβ–Ό βˆ’4.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
52.8%β–Ό βˆ’5.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$309Mβ–Ό βˆ’8.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$246Mβ–² +1.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.6Mβ–Ό βˆ’1.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.0Bβ–Ό βˆ’$958M YoY
StockOtter Β· stockotter.space

About PRESTIGE CONSUMER HEALTHCARE

Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Price Target

β“˜
Average Target
$52.18
β–² +11.7% Upside
High Target$60.38
Low Target$48.29
Based on 26 analysts

Latest News & Updates